Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDC-7035 in KRAS G12D-mutant advanced solid tumors
2024-515144-23-00Phase 2Authorised
- Sponsor
- Genentech
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 12
01
Overview
Phase 2, open-label trial of GDC-7035 and panitumumab in Nonhematologic neoplasms (2 arms), sponsored by Genentech. Primary endpoints: Incidence and severity of adverse events, Incidence and nature of dose-limiting toxicities and 3 more. Planned start May 2025; status: authorised.
02
Drugs
GDC-7035panitumumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2024-515144-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515144-23-00.